Exhibit 99.1
Joint Filer Information
Name of Joint Filer: | Knight Therapeutics Inc. |
Address of Joint Filer: | 3400 de Maisonneuve W. Suite 1055, Montréal, Quebec H3Z 3B8 |
Relationship of Joint Filer to Issuer: | Indirect Former 10% Beneficial Owner |
Issuer Name and Ticker or Trading Symbol: | 60 DEGREES PHARMACEUTICAL, INC. [SXTP] |
Date of Event Requiring Statement: | July 28, 2023 |
Designated Filer: | Knight Therapeutics Inc. |
Signature: |
KNIGHT THERAPEUTICS INC. | ||
By: | /s/ Samira Sakhia | |
Name: Samira Sakhia | ||
Title: President and Chief Executive Officer | ||
Date: April 3, 2024 |
Name of Joint Filer: | Knight Therapeutics International S.A. |
Address of Joint Filer: | Dr. Luis Bonavita 1294, of. 2004, Montevideo, Uruguay |
Relationship of Joint Filer to Issuer: | Direct Former 10% Beneficial Owner |
Issuer Name and Ticker or Trading Symbol: | 60 DEGREES PHARMACEUTICAL, INC. [SXTP] |
Date of Event Requiring Statement: | July 28, 2023 |
Designated Filer: | Knight Therapeutics Inc. |
Signature: |
KNIGHT THERAPEUTICS INTERNATIONAL S.A. | |||
By: | /s/ Arvind Utchanah | ||
Name: Arvind Utchanah | |||
Title: President of the Board of Directors | |||
Date: April 3, 2024 |
2